Home > DNA/RNA Synthesis & > Ifosfamide

Ifosfamide

异环磷酰胺,NSC109724,Isophosphamide,Ifex,NSC 109724,NSC-109724,

Ifosfamide是DNA烷化剂。Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer.

目录号
EY0281
EY0281
EY0281
纯度
99.57%
99.57%
99.57%
规格
50 mg
100 mg
250 mg
原价
240
420
590
售价
240
420
590
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Schoenike, S E., et al., 1990. Ifosfamide and mesna. Clinical pharmacy. 9(3): 179-91.
    [2] Creaven, P J., et al., 1976. Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724). Cancer treatment reports. 60(4): 445-9.
    [3] Skinner, R., et al., 1993. Ifosfamide, mesna, and nephrotoxicity in children. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 11(1): 173-90.

    分子式
    C7H15Cl2N2O2P    		 分子量
    261.09    		 CAS号
    3778-73-2    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    52 mg/mL    		 Water
    52 mg/mL    		 Ethanol
    52 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00880542 Sarcoma Drug: sorafenib|Drug: Ifosfamide Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Phase 2 2008-08-01 2015-10-28
    NCT01102608 Soft Tissue Sarcoma Drug: Ifosfamide Grupo Espanol de Investigacion en Sarcomas Phase 2 2008-03-01 2012-03-19
    NCT00003292 Chondrosarcoma|Adult Fibrosarcoma|Adult Leiomyosarcoma|Adult Rhabdomyosarcoma|Adult Malignant Meningioma|Adult Brain Malignant Hemangiopericytoma Drug: ifosfamide Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group Phase 2 1998-07-01 2013-11-07
    NCT00086970 Unspecified Adult Solid Tumor, Protocol Specific Drug: ifosfamide|Drug: O6-benzylguanine National Cancer Institute (NCI) Phase 1 2004-06-01 2013-01-23
    NCT01872416 Small Cell Lung Cancer Device: Liposomal Doxorubicin Combined With ifosfamide The First Affiliated Hospital of Guangzhou Medical University Phase 2 2012-10-01 2013-06-17
    NCT01784107 Small Cell Lung Cancer Drug: Belotecan and Ifosfamide Gachon University Gil Medical Center Phase 1|Phase 2 2011-07-01 2016-02-09
    NCT01749072 Non-small Cell Lung Cancer|Effects of Chemotherapy Drug: Gefitinib group|Drug: Vinorelbine, Ifosfamide, Mesna Peking Union Medical College Hospital Phase 2 2012-12-01 2012-12-12
    NCT02808247 Sarcoma, Soft Tissue Drug: Nintedanib|Drug: Ifosfamide European Organisation for Research and Treatment of Cancer - EORTC|Boehringer Ingelheim Phase 2 2017-01-01 2016-06-17
    NCT00289809 Sarcoma, Soft Tissue Drug: combination of TLC D-99 and Ifosfamide Istituto Clinico Humanitas Phase 1|Phase 2 2006-09-01 2009-12-17
    NCT02812654 Sarcoma, Soft Tissue Drug: Doxorubicin|Drug: Ifosfamide|Radiation: radiotherapy AC Camargo Cancer Center Phase 2 2015-03-01 2016-06-22
    NCT00231842 Uterine Cancer Drug: Ifosfamide|Procedure: Radiation Therapy Montefiore Medical Center Phase 2 2003-02-01 2012-04-22
    NCT02227199 Recurrent Adult Hodgkin Lymphoma|Refractory Hodgkin Lymphoma Drug: Brentuximab Vedotin|Drug: Carboplatin|Drug: Etoposide|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis University of Washington|National Cancer Institute (NCI) Phase 1|Phase 2 2014-10-10 2017-01-18
    NCT00502892 Solid Tumors Drug: Topotecan|Drug: Ifosfamide|Drug: Carboplatin M.D. Anderson Cancer Center Phase 1 2004-08-01 2012-07-31
    NCT01340547 Advanced Solid Tumors Drug: palifosfamide-tris|Drug: Normal Saline Ziopharm Phase 1 2011-06-01 2013-07-17
    NCT00515138 Lymphoma, B-Cell Drug: Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib University of California, San Francisco Early Phase 1 2007-05-01 2012-04-11
    NCT01300793 Non-Hodgkin's Lymphoma|B-cell Lymphoma Drug: Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide University of California, San Francisco|Millennium Pharmaceuticals, Inc. Phase 1 2007-05-01 2012-09-24

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：